The University of Queensland’s Molecular Clamp technology has been acquired by global healthcare giant Sanofi in a landmark deal worth up to US$1.6 billion – the largest involving a company commercialising intellectual property from an Australian university. Sanofi entered into an agreement to acquire Vicebio, a company formed in 2018 to develop UQ’s proprietary Molecular…
Pharmaceutical manufacturer IDT Australia has reported revenue for the quarter ended 30 September up 70 percent on the previous corresponding period to reach a two year high of $5.2 million. The Melbourne company said the results were encouraging and came on top of the it submitting proposals worth $24.7 million and securing $6.8 million in…
IDT Australia to raise $7 million for mRNA vaccine production Pharmaceutical manufacturer IDT Australia is to raise $7 million a fully underwritten entitlement offer of fully paid ordinary shares to eligible shareholders. The funds raised will be used to fund capital expenditure relating to current and potential future works in the mRNA therapeutics field including…
More rocket launches planned for Koonibba Test Range German rocket manufacturer Hyimpulse is negotiating further space launches from Southern Launch’s South Australian launch facilities following the successful launch its SL1 sub-orbital vehicle from the Koonibba Test Range near Ceduna, SA (pictured). The launch tested Hyimpulse’s novel propulsion technology. The company now plans further launches from…
What were the five biggest stories of the week? Here’s what visitors to this site were reading. 5) From soft plastics waste to structural building panels Australian composites manufacturer Sustainable Infrastructure Systems (SIS) has revealed innovative structural building panels made from glass fibre-reinforced polymer (GFRP) and discarded soft plastics. The lightweight, high-strength composite panels are…
Drug development company IDT Australia and pharmaceutical business Sanofi have signed an agreement for the good manufacturing practice (cGMP) manufacture of Sanofi’s mRNA vaccines now under development. The partners will collaborate to advance mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables filling facilities in Melbourne (pictured) in volumes needed for clinical trials…